Self-administered injectable drug–device combination (DDC) products are entering a phase of accelerated therapeutic innovation. Demographic change, chronic disease trends and the push for patient centric care are converging to make self administration a practical imperative rather than a futuristic aspiration. In the United States, the population aged over 50 years with at least one chronic disease is projected to increase by 99.5% from 71.5 million in 2020 to 142.7 million by 2050.1 As Baby Boomers and Generation X age and live longer with multiple conditions, predictable demand is emerging for therapeutic modalities that reduce the burden on health
systems while enabling patients to manage complex regimens at home. Established self-administration paradigms in diabetes are now informing approaches for other patient populations and different diseases.